Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

INCREASED SYSTEMIC HEPARANASE IN RETINAL VEIN OCCLUSION IS ASSOCIATED WITH ACTIVATION OF INFLAMMATION AND THROMBOPHILIA

Hu, Yijun, MD*,†; Yu, Yang, MMed; Bu, Zhanyun, MD§; Cun, Biyun, MD; Gong, Yi, MD**; Li, Dongli, MMed*; Li, Jianhua, MMed*; Lu, Li, MMed*; Li, Guodong, MD††; Yuan, Ling, MD, PhD*

doi: 10.1097/IAE.0000000000002374
Original Study: PDF Only

Purpose: To investigate the levels of systemic heparanase, inflammatory markers, and coagulation factor activities in patients with retinal vein occlusion (RVO).

Methods: This prospective study included 18 patients with central RVO, 22 patients with branch RVO, and 40 patients with age-related cataract as the control group. Serum heparanase protein levels and activities were measured by ELISA and a heparan degrading enzyme assay kit, respectively. Serum levels of MMP-2, MMP-9, TLR-2, and TLR-4 were measured by ELISA kits. The activities of coagulation factors (V, VII, VIII, and IX) were determined with an autoanalyzer. The Mann–Whitney U test was used to compare the above parameters between patients with RVO and control subjects. The relationship between two of the above parameters was analyzed by Spearman's correlation.

Results: Patients with RVO had higher levels of systemic heparanase protein, heparanase activities, coagulation factors' (V, VIII, and IX) activities, MMP-2, MMP-9, TLR-2, and TLR-4 compared with the control group. Systemic heparanase levels were correlated with serum levels of MMP-2, MMP-9, TLR-2, TLR-4, and activities of coagulation factors VIII and IX.

Conclusion: Increase of systemic heparanase in RVO is associated with activation of systemic inflammation and blood hypercoagulability.

We investigated the levels of systemic heparanase, inflammatory markers, and coagulation factor activities in patients with retinal vein occlusion. Systemic heparanase levels were found to be correlated with serum levels of MMP-2, MMP-9, TLR-2, TLR-4, and activities of coagulation factors VIII and IX.

*Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, Kunming, China;

Aier School of Ophthalmology, Central South University, Changsha, China;

Department of Ophthalmology, The Second People's Hospital of Qujing, Qujing, China;

§Department of Ophthalmology, Henan Provincial People's Hospital, Zhengzhou, China;

Clinical Skill Center, Kunming Medical University, Kunming, China;

**Department of Physiology, Kunming Medical University, Kunming, China; and

††Department of Ophthalmology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.

Reprint requests: Ling Yuan, MD, PhD, Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming 650031, China; e-mail: yuanling8061@163.com

Supported by the National Natural Science Foundation of China, Beijing, China (81760175), The Applied Basic Research Foundation of Yunnan Province, Yunnan, China (2016FB126).

None of the authors has any conflicting interests to disclose.

Y. Hu, Y. Yu, and Z. Bu contributed equally to the article and therefore can be considered as first coauthors. L. Yuan and G. Li are to be considered as the corresponding coauthors.

© 2018 by Ophthalmic Communications Society, Inc.